Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
about
Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndromeGuidelines for management of patients with a short bowelThe Pathogenesis of Resection-Associated Intestinal AdaptationExtensive Intestinal Resection Triggers Behavioral Adaptation, Intestinal Remodeling and Microbiota Transition in Short Bowel SyndromeManagement and Complications of Short Bowel Syndrome: an Updated Review.Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing.Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure.GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.Enteral nutrition in the management of pediatric intestinal failure.Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndromeThe role of gut hormones in glucose homeostasisEmerging treatment options for short bowel syndrome: potential role of teduglutideBench-to-bedside review: the gut as an endocrine organ in the critically illMechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblastsGlucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cellsRecent advances in small bowel diseases: Part II.Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Therapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male ratsEnteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.Intestinal mucosal atrophy and adaptationTeduglutide for the treatment of short bowel syndrome.New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome.Biologic actions and therapeutic potential of the proglucagon-derived peptides.Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritisGlucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.Promoting intestinal adaptation.Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials.Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel SyndromePediatric intestinal failure: nutrition, pharmacologic, and surgical approaches.Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion.Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats.A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patientsShort bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life.Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle functionEnteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport.Growth factors: possible roles for clinical management of the short bowel syndrome.GLP-2 delays but does not prevent the onset of necrotizing enterocolitis in preterm pigs.
P2860
Q24629712-F3E98E5C-EA9F-4B0E-8907-88F264F95CC5Q24646515-FBBCADF0-5E88-48AD-94F9-69EE38748A4AQ28076127-7CFBFA5A-4509-4004-8EFF-9F847447F636Q28076717-4DD5E186-08EF-4DFD-94F0-6C2B2827DFD7Q30249483-90F8F800-6E7D-42A6-90EF-C1BFDD2D000BQ33694525-75EB80A1-8C12-41E5-8F03-847B5B5D1409Q33865971-FECA54B4-ECBA-4BE3-8D66-EAC0D0BD41D0Q34425937-3844CFF3-5EDF-4E27-B822-FD6BA839C69FQ34494154-0F145A1E-F283-417E-8BB5-D7D492668CE4Q34617503-C7216A0D-A282-480D-AEE2-2D02DB6CE631Q35038334-E29C6E00-3676-41F9-B5F3-2BBA96F3A0DFQ35091974-ACD708EA-69C5-425E-969E-502E986C5380Q35141322-73A234E9-B57A-4298-8FA7-59A391630920Q35251016-0D12234E-2F95-4857-A3EB-5678F8D9AE4CQ35304614-DB99F605-607D-4690-869E-3EBCECDD9384Q35559137-C177BE57-BF6F-426D-ABCA-D44733E0F75BQ36063090-5452B565-8922-415B-811E-15737314AA5CQ36072565-EFB5084D-A3EF-471E-AE85-AD9060F91E62Q36093336-7CC209C5-3C6E-4557-BA51-0000D0EE17BFQ36171894-0A2D72B1-09F4-4730-A3DC-81CD7283A8E5Q36297218-2E1797C3-B21A-4084-92D1-A07E46F5DC3AQ36309586-2D1B63F1-9556-4739-9016-5B01CE16D408Q36429803-6CA6A5B0-2B56-4453-AE27-D4587F04B9D6Q36480664-58197423-01DF-4DC1-BD8B-E6A6801CE9B0Q36489336-3EF29340-1517-4FE7-989E-3B518A64F484Q36575421-27BEF720-A37F-4862-9977-630C617C5631Q36710034-B477EA4B-994D-443E-8934-5EA2CE62493BQ36710038-DAC718EF-6174-40A0-A98A-23565737A33FQ36721261-520E7D17-B692-4160-B0FC-6B5E43F2B4DBQ36751985-779FD7ED-15EB-4952-9568-314F040ADBB1Q36755774-65971595-A193-44A5-8E8D-8A07F92ADE5BQ37016607-5CBA9340-E456-45B6-9C71-512E46CC800CQ37138788-35E702FD-E977-4F26-AFA9-465E34EB14B6Q37200132-7229851F-941C-41FD-B57C-08C24E1FF2ACQ37247764-59DDC716-3063-45D0-897D-FD1792CB80CFQ37253453-6DB3D036-0D31-4966-9C71-009E6DD2A5F4Q37311786-A33F2D63-D5E9-4BBA-B075-F586EB2C14ACQ37662980-4ADD1C8E-2F1E-4B48-B8E2-F40BC22B08C4Q37685500-461B6E92-BEF4-4E3C-8472-C0BDD6053050Q37685841-E28B31C0-09BC-469B-806A-A0959F906E45
P2860
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Teduglutide (ALX-0600), a dipe ...... short bowel syndrome patients.
@ast
Teduglutide (ALX-0600), a dipe ...... short bowel syndrome patients.
@en
type
label
Teduglutide (ALX-0600), a dipe ...... short bowel syndrome patients.
@ast
Teduglutide (ALX-0600), a dipe ...... short bowel syndrome patients.
@en
prefLabel
Teduglutide (ALX-0600), a dipe ...... short bowel syndrome patients.
@ast
Teduglutide (ALX-0600), a dipe ...... short bowel syndrome patients.
@en
P2093
P2860
P356
P1433
P1476
Teduglutide (ALX-0600), a dipe ...... short bowel syndrome patients.
@en
P2093
E L Sanguinetti
J S Scolapio
K A Tappenden
P B Jeppesen
P B Mortensen
T R Ziegler
P2860
P304
P356
10.1136/GUT.2004.061440
P407
P577
2005-09-01T00:00:00Z